Purpose

A randomized, controlled, non-placebo trial to primarily assess the effect of oral, outpatient antibiotics (i.e., azithromycin and amoxicillin) on latency (i.e., proportion of patients that deliver within 28 days from membrane rupture) following previable, prelabor rupture of membranes between 18 0/7 and 22 6/7 weeks gestational age.

Conditions

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
Female
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • English-speaking - Pregnant - Live, singleton gestation - Patient able to provide informed consent - Gestational age between 18 weeks and 0 days and 22 weeks and 6 days at the time of -membrane rupture - Diagnosis of preterm, prelabor rupture of membranes by clinical exam findings of either 1) visualization of amniotic fluid passing from the cervical canal and/or pooling in the vagina via sterile speculum examination, 2) a basic pH (i.e., positive nitrazine) test of vaginal fluid, 3) arborization (i.e., ferning) of dried vaginal fluid identified via microscopic examination, and/or 4) an amniotic fluid index (AFI) of less than 4cm

Exclusion Criteria

  • Gestational dating performed or confirmed by ultrasound at ≥ 18 weeks and 0 days gestational age - Patient desires pregnancy interruption or induction of labor - Known major fetal anomaly or aneuploidy - Amniocentesis ≤ 7 days of diagnosis of rupture of membranes - Cervical cerclage placement ≤ 7 days of diagnosis of rupture of membranes - Known drug allergy or significant adverse reactions to macrolide or penicillin antibiotics - Current antibiotic use at the time of membrane rupture diagnosis - Vaginal bleeding at the time of membrane rupture diagnosis or within first 24 hours from diagnosis - Febrile at the time of membrane rupture diagnosis (i.e., temperature ≥ 38 degrees Celsius) and/or within first 24 hours of diagnosis - Active preterm labor at the time of membrane rupture diagnosis (i.e., consistent contraction pattern associated with cervical change) and/or within first 24 hours of diagnosis - Cervical dilation of ≥ 4 cm - Prolapse of fetal parts beyond the level of the internal cervical os - Declination to complete full, 7-day outpatient monitoring prior to hospital re-admission should rupture occur during the 22nd week of gestation

Study Design

Phase
Phase 4
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Antibiotics
Patients randomized into the treatment (i.e., antibiotics) arm of the study will be treated with a seven-day course of oral azithromycin and amoxicillin. Azithromycin will be dosed as single 500 mg dose (2-250mg oral tablets) administered immediately following randomization, yet prior to discharge to home, followed with 1-250mg oral tablet daily for 4 additional days (for a total of 5 days). Amoxicillin will be dosed as a single-500mg oral tablet three times daily for 7 days with first dose also being given prior to discharge home.
  • Drug: Azithromycin Pill
    Azithromycin will be dosed as single 500 mg dose (2-250mg oral tablets) administered immediately following randomization, yet prior to discharge to home, followed with 1-250mg oral tablet daily for 4 additional days (for a total of 5 days).
  • Drug: Amoxicillin Pill
    Amoxicillin will be dosed as a single-500mg oral tablet three times daily for 7 days with first dose also being given prior to discharge home.
No Intervention
No antibiotics
Patients randomized into the control (i.e., no antibiotics arm) will be managed according to standard of care practices for previable PPROM desiring of expectant management.

Recruiting Locations

MetroHealth
Cleveland, Ohio 44109
Contact:
Felicia LeMoine, MD
216-983-6606
felicia.lemoine@uhhospitals.org

More Details

Status
Recruiting
Sponsor
University Hospitals Cleveland Medical Center

Study Contact

Felicia LeMoine, MD
(216) 983-6606
felicia.lemoine@uhhospitals.org

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.